Company Milestones  
Home > About Us > Company Milestones
 
 
2021
 
07 Mass Production of Triple-Injection Synovial Fluid Supplement in the Biotech Plant 1
 
2020
 
04 Absorbable Nasal Dressing Launched
05 Mass Production of Single-Injection Synovial Fluid Supplement in the Biotech Plant 1
HYAJOINT Plus Synovial Fluid Supplement is Approved by Pricing System for Pharmaceuticals (Single Injection per Year) under the Scheme of Taiwan National Health Insurance System
07 Stablized Synovial Fluid Supplement Launched
09 HYAJOINT Synovial Fluid Supplement is Approved by TFDA for the New Indication of Shoulder Rotator Cuff Lesions without Complete Tears
11 Approval of HALAL Assurance System (HAS)
12 PROTAHERE Absorbable Adhesion Barrier Won the Silver Award in “2020 Research and Development of Pharmaceutical Technology Award”
 
2019
 
06 Awarded with the "16th the National Brand YuShan Award" as an Outstanding Enterprise
07 Sodium Hyaluronate Facial Dermal Implant with Lidocaine in Gel Type Launched
The Biotech Plant 1 is ISO 13485 Certified
08 The Biotech Plant 1 is GMP Certified for the Class Ⅲ Medical Device by the Ministry of Health and Welfare, Republic of China (Taiwan)
 
2018
 
08 DEFEHERE Absorbable Adhesion Barrier Launched in Taiwan
09 Sodium Hyaluronate Facial Dermal Implant with Lidocaine is CE-MDD 93/42/EEC (ClassIII) Certified and Obtained the CE Marking
 
2017
 
01 Sodium Hyaluronate Intravesical Instillation Launched
02 PROTAHERE Absorbable Adhesion Barrier Launched
03 European Patent for the Technique of Cross-linked Hyaluronic Acid Platform (CHAP) Granted
06 Approval of Sedex Members Ethical Trade Audit (SMETA)
 
2016
 
05 Sodium Hyaluronate Wound Repair Hydrogel Launched
06 U.S. Patent for the Technique of Cross-linked Hyaluronic Acid Platform (CHAP) Granted
08 Signed an Exclusive Distribution Agreement with GALDERMA S.A. (Subsidiary of Nestlé)
 
2015
 
10 Approval of Subsidy Project of Investing Development and Promoting Industry from the Kaohsiung City Government
 
2014
 
04 Sodium Hyaluronate Facial Dermal Implant Launched in China
Passed the GMP Inspection by Korea Competent Authority
05 Approval of Canadian Medical Devices Conformity Assessment System (CMDCAS) Certification
 
2013
 
03 Taiwan Patent for the Technique of Cross-linked Hyaluronic Acid Platform (CHAP) Granted
11 Japan Patent for the Technique of Cross-linked Hyaluronic Acid Platform (CHAP) Granted IPOs (Initial Public Offerings) Launched in Taiwan
Sodium Hyaluronate Facial Dermal Implant with Lidocaine Launched
12 Approval of Taiwan Intellectual Property Management System (TIPS) Certification
 
2012
 
02 Single-Injection Synovial Fluid Supplement Launched
10 Awarded with the “National Industry Innovation Award” from the Ministry of Economic Affairs
Awarded with the “National New Innovation Award” from the Institute for Biotechnology and Medicine Industry
 
2011
 
05 Sodium Hyaluronate Hydrogel Wound Dressing Launched
06 Sodium Hyaluronate Facial Dermal Implant Launched in Korea
12 China Patent for the Technique of Cross-linked Hyaluronic Acid Platform (CHAP) Granted
 
2010
 
02 Sodium Hyaluronate Facial Dermal Implant Launched
Triple-Injection Synovial Fluid Supplement Launched in Philippines
Sodium Hyaluronate Facial Dermal Implant Launched in Italy
12 Listed on the Taipei Exchange (TPEx) with Emerging Stock Market Code 1786
 
2009
 
01 Sodium Hyaluronate Facial Dermal Implant Launched in India
02 Program for Development of New Leading Products, Facial Dermal Implant of Crosslinked Hyaluronan, was Approved by the Industrial Development Bureau, Ministry of Economic Affairs
05 Listed as Biotech and New Pharmaceutical Industry by the Industrial Development Bureau, Ministry of Economic Affairs
The ITDP-Fast Track for Clinical Trial Program, Sodium Hyaluronate Facial Dermal Implant Clinical Trial Project, was Approved by the Ministry of Economic Affairs
08 The Small Business Innovation Research (SBIR), Single-Injection Synovial Fluid Supplement R&D Project, was Approved by the Kaohsiung City Government
 
2008
 
08 Triple-Injection Synovial Fluid Supplement Launched
12 HYAJOINT Synovial Fluid Supplement was Awarded the “National Biomedical Quality Award”
 
2006
 
01 The Export Permit for HYADERMIS Facial Dermal Implant was Issued by the Department of Health, Executive Yuan. Registration No. DOH-MD-(E)-No. 000028
The Export Permit for HYAJOINT Synovial Fluid Supplement was Issued by the Department of Health, Executive Yuan. Registration No. DOH-MD-(E)-No. 000029
08 Triple-Injection Synovial Fluid Supplement Launched in India
 
2005
 
01 Achieved the ISO 9001 and ISO 13485 Certification for Medical Device Quality Management System
03 Sodium Hyaluronate Facial Dermal Implant was CE-MDD 93/42/EEC (Class III) Certified and Obtained the CE Marking
07 Awarded with the “Product Innovation Leadership Award of the Biomedical Material Category” from the Frost & Sullivan Awards.
09 The Medical Device Plant was GMP Certified for the Class Ⅲ Medical Device by the Department of Health, Executive Yuan
12 Sodium Hyaluronate Synovial Fluid Supplement was CE-MDD 93/42/EEC (Class III) Certified and Obtained the CE Marking
Awarded with the “Export Processing Zone Innovative Research and Development Award” from the Ministry of Economic Affairs
 
2004
 
09 Awarded with the “Investment Incentive Program” from the Kaohsiung City Government
 
2003
 
03 Achieved the CNLA Certification (The First Certified Parentage Testing Laboratory in Taiwan).
12 Program for Development of New Leading Products, Medical Grade Hyaluronic Acid, was Approved by the Ministry of Economic Affairs
 
2002
 
10 Achieved the ISO 9001 Certification